用克拉屈滨和高剂量阿糖胞苷治疗难治或复发的急性髓系白血病。
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
机构信息
Department of Medicine, Queen Mary Hospital, Hong Kong, China.
出版信息
Ann Hematol. 2011 Nov;90(11):1277-81. doi: 10.1007/s00277-011-1223-2. Epub 2011 Apr 1.
Abstract
Clofarabine (40 mg/m(2)/day × 5) and high-dose cytosine arabinoside (Ara-C, 1-2 g/m(2)/day × 5) were used in 10 men and 11 women, at a median age of 45 (22-62) years, with refractory (N = 4) and relapsed (N = 17) acute myeloid leukaemia, after a median of 3 (2-5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m(2)/day and not 1 g/m(2)/day (9/15 versus 0/4, P = 0.03).
摘要
在 10 名男性和 11 名女性患者中，中位年龄为 45 岁（22-62 岁），在中位先前接受 3 种（2-5 种）方案后，使用了氯法拉滨（40mg/m²/天×5 天）和高剂量阿糖胞苷（Ara-C，1-2g/m²/天×5 天），他们患有难治性（N=4）和复发性（N=17）急性髓细胞白血病。所有患者均出现 4 级骨髓抑制，有 2 例患者死于细菌性败血症。9 例患者达到完全缓解。疾病状态、先前治疗次数和细胞遗传学异常与结局无关。然而，仅在 Ara-C 剂量为 2g/m²/天时才能达到缓解（9/15 例，而 1g/m²/天时为 0/4 例，P=0.03），而非 1g/m²/天时。
相似文献
1
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Ann Hematol. 2011 Nov;90(11):1277-81. doi: 10.1007/s00277-011-1223-2. Epub 2011 Apr 1.
2
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544. Epub 2013 Sep 9.
3
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Ann Hematol. 2014 Jun;93(6):965-75. doi: 10.1007/s00277-014-2056-6. Epub 2014 Mar 29.
4
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Oncologist. 2011;16(2):197-206. doi: 10.1634/theoncologist.2010-0220. Epub 2011 Jan 27.
5
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Am J Hematol. 2012 Dec;87(12):1047-51. doi: 10.1002/ajh.23308. Epub 2012 Aug 1.
6
Clofarabine-based consolidation therapy in AML.
Lancet Oncol. 2017 Apr;18(4):e201. doi: 10.1016/S1470-2045(17)30177-8. Epub 2017 Mar 3.
7
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14.
8
Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
Jpn J Clin Oncol. 2013 Dec;43(12):1177-83. doi: 10.1093/jjco/hyt155. Epub 2013 Oct 14.
9
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25.
10
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18.
引用本文的文献
1
Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Cancer Med. 2020 May;9(10):3371-3382. doi: 10.1002/cam4.2865. Epub 2020 Mar 18.
2
Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Curr Hematol Malig Rep. 2014 Jun;9(2):186-92. doi: 10.1007/s11899-014-0209-2.
3
High-dose cytarabine (HD araC) in the treatment of leukemias: a review.
Curr Hematol Malig Rep. 2013 Jun;8(2):141-8. doi: 10.1007/s11899-013-0156-3.
4
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18.
本文引用的文献
1
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Br J Haematol. 2010 Dec;151(5):430-4. doi: 10.1111/j.1365-2141.2010.08387.x.
2
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12.
3
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
Blood. 2010 Jul 22;116(3):354-65. doi: 10.1182/blood-2009-11-254441. Epub 2010 Apr 12.
4
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
J Clin Oncol. 2010 Feb 1;28(4):549-55. doi: 10.1200/JCO.2009.23.3130. Epub 2009 Dec 21.
5
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Am J Hematol. 2009 Nov;84(11):733-7. doi: 10.1002/ajh.21545.
6
Clofarabine: emerging role in leukemias.
Expert Opin Investig Drugs. 2009 Oct;18(10):1559-64. doi: 10.1517/13543780903173222.
7
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer. 2008 Oct 15;113(8):2090-6. doi: 10.1002/cncr.23816.
8
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood. 2008 Sep 1;112(5):1638-45. doi: 10.1182/blood-2007-11-124602. Epub 2008 Jun 18.
9
Biology and management of relapsed acute myeloid leukaemia.
Br J Haematol. 2005 Apr;129(1):18-34. doi: 10.1111/j.1365-2141.2004.05318.x.
10
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood. 2005 Feb 1;105(3):940-7. doi: 10.1182/blood-2004-05-1933. Epub 2004 Oct 14.
Zotero 插件